Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal females with a history of hormone receptor-positive breast cancer and obesity. The investigators aim to understand whether participants are willing and able to take this medication once weekly for 6 months and whether it may help improve weight and overall health. There will be monthly check-ins to monitor progress and safety. At the beginning and end of the study, participants will undergo body composition assessments, blood tests and a stool sample will be collected, and surveys will be com

Trial Details

NCT ID

NCT07257484

Phase

PHASE4

Sponsor

Weill Medical College of Cornell University

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

• Tirzepatide

Locations (sample)

• New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

• Biologically female
• Obesity as defined by current BMI ≥ 30 kg/m² or ≥ 27.5 kg/m² for individuals of Asian ancestry
• Postmenopausal as defined by one or more of the following
• Age ≥60 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →